Breast Cancer

The Oncotype DX 21-gene recurrence score helps guide adjuvant therapy in women with early-stage breast cancer and low genomic risk.

The Breast Cancer Index and artificial intelligence–assisted mammograms are tools that can help mitigate symptoms and reassure patient insecurities of women with breast cancer post-treatment.

Oranus Mohammadi, MD, discusses the emerging applications of circulating tumor DNA (ctDNA) in breast cancer care and emphasizes the importance of clear communication to help patients navigate uncertain or anxiety-provoking biomarker test results.

Joanne Mortimer, MD, FACP, FASCO, discusses the practical applications and limitations of circulating tumor DNA (ctDNA) testing in breast cancer, highlighting its role in guiding targeted therapy, challenges in patient communication and payer coverage, and unique barriers for male patients.

A clinical trial assessing a remote weight loss intervention in women with breast cancer saw a reduction in body weight.

Artificial intelligence (AI) can reduce radiologist workload for breast cancer screenings and mammograms, but their review of the results is still crucial, explained Sarah Verboom of Radboud University Medical Center.

Treatment challenges that Anasuya Gunturi, MD, PhD, encounters in her work at Lowell General Hospital include language differences and confusion about scheduled appointments.

RIsing costs for therapies and inequities in reimbursement for genomic testing have created financial barriers for patients, according to appearing experts in Detroit, Michigan, on July 10, 2025.

Artificial intelligence (AI) can enhance breast cancer screenings by prioritizing cases, allowing radiologists to focus on complex diagnoses and improve detection rates, explained Sarah Verboom of Radboud University Medical Center.

New research reveals how triple-negative breast tumors use fatty tissue to fuel growth, highlighting the role of gap junctions in tumorigenesis.

AI enhances mammography by reducing radiologists' workload by 40% while maintaining accuracy in breast cancer detection, according to recent research.

AI-enhanced mammograms have potential to improve breast cancer screenings, facilitating early detection and empowering women's health decisions.

Despite its potential, incorporating new treatments like T-DXd into a first-line setting faces several barriers, explains Michael Hassett, MD, MPH, chief quality officer at Dana-Farber Cancer Institute in Boston.

Patient satisfaction was higher amongst patients who underwent a chest wall perforator flap reconstruction surgery as part of their breast cancer treatment when compared with other surgical techniques.

The Pennsylvania Act 1 of 2023 eligibility criteria for supplemental screenings based on breast density and lifetime risk of breast cancer disproportionately disqualify Black women from supplemental screenings despite their high risk of aggressive cancer and persistent history of false-negative mammograms.

Disparities in access to quality treatment and lack of equitable and inclusive data in breast cancer research contribute to poorer survival outcomes for Black women with breast cancer.

Early-onset breast cancer was associated with hormone therapy usage in younger women in a recent study.

At the recent regional Institute for Value-Based Medicine® event in Boston, Anasuya Gunturi, MD, PhD, Lowell General Hospital, was a panelist for the discussion, “Evolving Breast Cancer Care: Addressing Unmet Needs Across the Patient Journey.”

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer treatment continuum.

Rebecca Chacko, MD, discussed exciting advancements in breast cancer care and the future role of emerging therapeutic strategies for early recurrence detection, as part of her panelist role at the Detroit Institute for Value-Based Medicine.

Rebecca Chacko, MD, discusses key breast cancer care challenges, including treatment access delays and the importance of open patient communication, as highlighted at the Detroit Institute for Value-Based Medicine session on unmet needs.

Estrogen-progestin hormone therapy used to manage menopausal symptoms and other women’s health conditions is associated with a higher risk of developing luminal-like breast cancer subtypes and other subtypes.

Women who developed a cardiovascular disease or type 2 diabetes were at a higher risk of developing breast cancer post menopause, a recent study found.

Dr Rugo discusses the promising outcomes of trastuzumab deruxtecan for HER2+ breast cancer, addressing interstitial lung disease risks and retreatment strategies.